Inventor
HUANG LIANFENG
US34 patents
⚠️ This page may combine multiple inventors who share the name “HUANG LIANFENG”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CELGENE CORP
18 patentsUS11013723B1May 25, 2021
Solid forms of a thiazolidinone compound, compositions and methods of use thereof
CELGENE CORP2 citations72
US11680046B2Jun 20, 2023
Crystalline (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, compositions and methods of use thereof
CELGENE CORP1 citations69
US11053199B2Jul 6, 2021
Crystalline (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, compositions and methods of use thereof
CELGENE CORP2 citations69
US11014897B1May 25, 2021
Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
CELGENE CORP0 citations62
US11701362B2Jul 18, 2023
Compositions and methods of use of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1- methylcyclohexane-1-carboxamide
CELGENE CORP0 citations61
US10898488B2Jan 26, 2021
Compositions and methods of use of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide
CELGENE CORP0 citations61
US12583837B2Mar 24, 2026
Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising and methods of using the same
CELGENE CORP0 citations60
US11578056B2Feb 14, 2023
Solid forms comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising and methods of using the same
CELGENE CORP0 citations60
US12410133B2Sep 9, 2025
Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, compositions and methods of use thereof
CELGENE CORP0 citations59
US12391672B2Aug 19, 2025
Solid forms comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same
CELGENE CORP0 citations57
US11370777B2Jun 28, 2022
Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same
CELGENE CORP0 citations56
US11186556B1Nov 30, 2021
Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
CELGENE CORP0 citations51
US9795650B2Oct 24, 2017
Romidepsin formulations and uses thereof
CELGENE CORP0 citations51
US9782451B2Oct 10, 2017
Romidepsin formulations and uses thereof
CELGENE CORP0 citations51
US9468664B2Oct 18, 2016
Romidepsin formulations and uses thereof
CELGENE CORP0 citations51
US9463215B2Oct 11, 2016
Romidepsin formulations and uses thereof
CELGENE CORP0 citations51
US10653697B2May 19, 2020
Compositions and methods of use of cis-4-[2-{[3S,4R)-3-fluorooxan-4-yl]amino}8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide
CELGENE CORP0 citations50
US10543214B2Jan 28, 2020
Compositions and methods of use of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide
CELGENE CORP0 citations50
SIGNAL PHARM LLC
7 patentsUS9814713B2Nov 14, 2017
Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
SIGNAL PHARM LLC14 citations92
US9365524B2Jun 14, 2016
Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
SIGNAL PHARM LLC22 citations92
US9796685B2Oct 24, 2017
Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-Methylcyclohexylamino)-pyrimidine-5-carboxamide
SIGNAL PHARM LLC14 citations89
US10590089B2Mar 17, 2020
Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
SIGNAL PHARM LLC1 citations70
US10131639B2Nov 20, 2018
Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4methylcyclohexylamino)-pyrimidine-5-carboxamide
SIGNAL PHARM LLC4 citations70
US10047090B2Aug 14, 2018
Solid forms of (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use
SIGNAL PHARM LLC3 citations68
US10513519B2Dec 24, 2019
Solid forms of (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use
SIGNAL PHARM LLC0 citations47
CELGENE CAR LLC
4 patentsUS10882867B2Jan 5, 2021
Forms and compositions of a MK2 inhibitor
CELGENE CAR LLC8 citations82
US11629153B2Apr 18, 2023
Forms and compositions of a MK2 inhibitor
CELGENE CAR LLC1 citations60
US10005760B2Jun 26, 2018
Forms and compositions of an ERK inhibitor
CELGENE CAR LLC1 citations60
US10202364B2Feb 12, 2019
Forms and compositions of an ERK inhibitor
CELGENE CAR LLC0 citations49
NOVARTIS AG
4 patentsUS11434200B2Sep 6, 2022
Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
NOVARTIS AG2 citations72
US12049446B2Jul 30, 2024
Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
NOVARTIS AG0 citations62
US11958805B2Apr 16, 2024
Solid forms comprising an oxime ether compound, compositions and methods of use thereof
NOVARTIS AG0 citations62
US11629124B2Apr 18, 2023
Solid forms comprising an oxime ether compound, compositions and methods of use thereof
NOVARTIS AG1 citations62